Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by the AGA Institute.
Educational Partner: 
Support Statement: This activity is supported by an educational grant from Pfizer, Inc.
Target Audience: The target audience for this educational activity is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Screen patients with IBD for infectious diseases before initiating immunosuppressive therapies.
- Assess the risk of infection with established and emerging immunosuppressive therapies used in the treatment of IBD.
- Apply preventive measures and the appropriate immunizations to patients with IBD according to established evidence-based guidelines.
- Establish procedures that improve the multidisciplinary approach to care, improve immunization rates, and educate patients about preventive measures that can reduce the risk of infection.
Activity Chair:
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
Faculty:
Francis A. Farraye, MD, MSc
Clinical Director, Section of Gastroenterology
Professor of Medicine
Boston University School of Medicine
Boston, MA
David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Reviewer:
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
Accreditation:
The American Gastroenterological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation:
The American Gastroenterological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, March 12, 2018 through March 11, 2019.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, the American Gastroenterological Association will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationship(s):
Francis A. Farraye, MD, MSc
Consulting Fee: Janssen, Merck, Pfizer, Takeda
Ownership Interest: Cellceutix (Innovation Pharmaceuticals)
Other Disclosure: Data Safety & Monitoring Board: Protagonist
Gary R. Lichtenstein, MD
Royalty: SLACK Incorporated
Consulting Fee: Abbott/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer, Prometheus, Romark, Salix, Santarus, Shire, Takeda, UCB
Contracted Research: Ferring, Prometheus, Salix, Santarus, Shire, UCB
Research Grant (paid to institution): Janssen Orthobiotech
Author Honoraria: McMahon Publishing, UptoDate
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media
David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Consulting Fee: AbbVie, Abgenomics, Allergan, Amgen, Celgene, Forward Pharma, Genentech/Roche, Janssen, Merck, Miraca Life Sciences, Napo Pharmaceuticals, Pfizer, Samsung Bioepis, Sandoz, Shire, Takeda
Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda, UCB
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com